CN102994412B - 一种空间环境下大肠杆菌lct-ec52菌株 - Google Patents
一种空间环境下大肠杆菌lct-ec52菌株 Download PDFInfo
- Publication number
- CN102994412B CN102994412B CN201210380121.4A CN201210380121A CN102994412B CN 102994412 B CN102994412 B CN 102994412B CN 201210380121 A CN201210380121 A CN 201210380121A CN 102994412 B CN102994412 B CN 102994412B
- Authority
- CN
- China
- Prior art keywords
- escherichia coli
- lct
- space
- space environment
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000894006 Bacteria Species 0.000 title claims description 15
- 241000588724 Escherichia coli Species 0.000 claims abstract description 26
- 206010059866 Drug resistance Diseases 0.000 claims abstract description 9
- 229960004099 azithromycin Drugs 0.000 claims description 5
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 229960000484 ceftazidime Drugs 0.000 claims description 4
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 claims description 4
- 229960004755 ceftriaxone Drugs 0.000 claims description 4
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 4
- CWKLZLBVOJRSOM-UHFFFAOYSA-N methyl pyruvate Chemical compound COC(=O)C(C)=O CWKLZLBVOJRSOM-UHFFFAOYSA-N 0.000 claims description 3
- BFPJYWDBBLZXOM-UHFFFAOYSA-L potassium tellurite Chemical compound [K+].[K+].[O-][Te]([O-])=O BFPJYWDBBLZXOM-UHFFFAOYSA-L 0.000 claims description 3
- XUXNAKZDHHEHPC-UHFFFAOYSA-M sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 claims description 3
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N 1-Pyrroline Chemical compound C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 abstract description 12
- 244000005700 microbiome Species 0.000 abstract description 7
- 230000007246 mechanism Effects 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000001018 virulence Effects 0.000 abstract description 3
- 238000012268 genome sequencing Methods 0.000 abstract description 2
- 230000019522 cellular metabolic process Effects 0.000 abstract 1
- 230000003950 pathogenic mechanism Effects 0.000 abstract 1
- 238000000575 proteomic method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 21
- 241001135840 Escherichia coli LCT-EC52 Species 0.000 description 12
- 239000012634 fragment Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 108020004465 16S ribosomal RNA Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 6
- 108010026552 Proteome Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000012070 whole genome sequencing analysis Methods 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 229960001139 cefazolin Drugs 0.000 description 3
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000007918 pathogenicity Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000005487 simulated microgravity Effects 0.000 description 2
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012437 strong cation exchange chromatography Methods 0.000 description 2
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- 102100034612 Annexin A4 Human genes 0.000 description 1
- 108090000669 Annexin A4 Proteins 0.000 description 1
- 108010082340 Arginine deiminase Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016862 Dicarboxylic Acid Transporters Human genes 0.000 description 1
- 108010092943 Dicarboxylic Acid Transporters Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100324049 Escherichia coli (strain K12) arnB gene Proteins 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000012435 Phosphofructokinase-1 Human genes 0.000 description 1
- 108010022684 Phosphofructokinase-1 Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005567 fecaloral disease transmission Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940104641 piperacillin / tazobactam Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960005256 sulbactam Drugs 0.000 description 1
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000012049 whole transcriptome sequencing Methods 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及空间环境下大肠杆菌及其基因组序列。既往研究发现空间环境能够影响微生物的许多特征,例如生长速率、细胞形态、细胞代谢水平、生物被膜的产生、毒力和耐药性的增加或者降低。本发明利用太空特殊环境,通过搭载神舟八号飞船将大肠杆菌送入太空,历经398小时、1100万公里的飞行后返回地面,进行了表型相关实验,证明了空间环境诱变的大肠杆菌菌株存在明显的变化。随后对该菌株进行了基因组测序、转录组测序、和蛋白质组学分析,旨在发现发生这些变化的潜在机制及其应用。随着对这些问题的深入研究,有利于我们发现和了解空间环境对大肠杆菌的影响和致病性机制,为保障航天员安全提供了理论基础。
Description
技术领域
本发明属于生物技术领域,涉及一种空间环境下的大肠杆菌生物特性、全基因组测序、转录组测序和差异蛋白组学分析。
背景技术
随着人类空间探索活动的日益频繁,宇宙空间成为了人类活动的一个重要领域。微生物是自然环境中的一部分,其存在于空气、水、土壤等生物圈的各个部分。因此,人类的空间活动不可避免的将微生物也带上了太空。尽管外层空间具有极端和复杂的环境,然而这些微生物都能够适应这些诸如微重力、宇宙射线、温度、压力等的改变并表现出相应的形态和生理学的变化。尤其是有研究发现在模拟微重力条件下培养的鼠伤寒沙门氏菌对小鼠感染的毒力会增强;肺炎链球菌等机会致病菌在模拟微重力条件下毒力增强。目前,在空间站中已检测出包括肺炎克雷伯氏菌、金黄色葡萄球菌、铜绿假单胞菌、大肠杆菌、沙雷氏菌、蜡状芽孢杆菌和肠球菌等多种细菌。对这些细菌进行深入研究有助于了解空间环境对这些细菌的影响以及这些细菌的致病力和耐药性的改变机制,为载人航天提供医学保障基础。
大肠杆菌是存在于恒温动物肠道中的一种革兰氏阴性圆形杆菌。大多数的大肠杆菌的菌株是没有危害的,但是一些血清型可以导致人类严重的食物中毒。没有危害的大肠杆菌是肠道的正常菌群的一部分,其产生维生素K2对宿主是有益的,而且还能防止肠道中其他致病性病源菌的生成。大肠杆菌占整个肠道菌群的0.1%,粪口传播途径是该病原菌致病的重要途径。同时大肠杆菌是被广泛研究的原核模式生物,因其可作为重组DNA的宿主,是微生物学和生物技术领域的一个重要的细菌。正因为大肠杆菌具有如此重要的作用,通过表型研究空间环境下的细菌突变株,并利用基因组、转录组、蛋白质组三大组学研究方法,研究细菌对空间环境的适应性变化,关注其致 病性、耐药性的变化,为预防感染性疾病在空间站中的发生奠定基础。
发明内容
本发明的目的是提供一种太空环境下的大肠杆菌菌株LCT-EC52。通过表型检测、全基因组测序,并结合转录组学和蛋白组学阐明该细菌受空间影响的变化机制。
本发明提供的菌株LCT-EC52,其保藏号为CGMCC6518。
所述的大肠杆菌LCT-EC52,其表型特征为:革兰氏阴性杆菌,无芽孢,菌体单个排列;对氨苄西林、头孢唑林、头孢他啶、头孢三嗪、阿奇霉素的耐药性出现了完全耐药;不能利用D-水杨、甲基丙酮酸、亚碲酸钾、溴酸钠等。
所述的大肠杆菌LCT-EC52进行全基因组测序和比较基因组学分析得出突变基因,见表1,空间环境导致LCT-EC52菌株基因组上SNP的变化,包括SNP在基因组上的位置,突变位点及编码蛋白以及注释出的基因。
表1空间环境导致LCT-EC52菌株基因组上SNP的变化
所述的大肠杆菌LCT-EC52,通过转录组测序鉴定获得差异表达基因,(FDR≤0.001和|log2Ratio|≥2)见附表1。
所述的大肠杆菌LCT-EC52,利用蛋白组学方法鉴定得出差异表达蛋白分子(蛋白丰度差异倍数超过2倍以上时;经统计检验其p-value值小于0.05;三次重复中至少两次重复中达到上述要求)见附表2。
附图说明
图1大肠杆菌LCT-EC52革兰氏染色
图2大肠杆菌空间菌株LCT-EC52的Biolog生化特征
图3大肠杆菌LCT-EC52菌株与地面对照株LCT-EC106的生长曲线
图4大肠杆菌空间环境下菌株LCT-EC52的转录组基因覆盖度统计
图5大肠杆菌空间环境下菌株LCT-EC52的转录组差异表达基因
图6大肠杆菌空间环境下菌株LCT-EC52的蛋白组差异表达蛋白
附件说明
附件1大肠杆菌LCT-EC52转录组测序差异表达基因信息
附件2大肠杆菌LCT-EC52蛋白组差异表达蛋白信息
具体实施方式
下述实施实例中所用的实验方法,如无特殊说明,均为常规方法。
下述实施实例中所用的材料、试剂,如无特殊说明,均可从商业途径获得。
具体实施实例一LCT-EC52的表型
1.菌种:大肠杆菌LCT-EC52保藏号为:CGMCC
2.形态学:原样品进行稀释涂布,进行革兰氏染色。LCT-EC52为革兰氏阴性杆菌,无芽孢,菌体单个排列,如图1。
3.LCT-EC52菌株16s rDNA鉴定:16S rDNA是16S rRNA序列的基 因,长约1.5kb。将已分纯的单菌直接经菌液PCR扩增16S rDNA,部分通过菌液PCR较难扩增的单菌经扩大培养后提取基因组后扩增,扩增所用引物序列如下:SgF(AGAGTTTGATCATGGCTCAG),SgR(TAGGGTTACCTTGTTACGACTT),16S rDNA PCR产物用96孔millpore纯化系统纯化后准确定量,经ABl3730xl全自动序列分析仪测序,测序结果使用Seq uence scanner、Seqman等序列分析软件,将两向测序结果去掉首尾不可信序列后拼接,余下的约1350bp(双向测序)即用于同源性分析。所得16S rDNA序列在Eztaxon server2.1数据库中进行比对,确定菌株大致的分类地位。所有单菌16S序列全部导入seqman,输出singlefile(fasta)后,经Mega5.0软件clusterW多重比对,输出meg文件重新导入构建Neighbor-Joining tree。其中,phylogeny test method为bootstrap参数设置为1000。16s rDNA鉴定结果显示LCT-EC52与Escherichia coliKCTC2441(T)的相似性为99.826%。
4.耐药性检测:配制菌悬液后稀释涂布,粘贴药敏片,选择的抗生素为青霉素G、氨苄青霉素、头孢唑林、复达欣(头孢他啶)(头孢噻甲羧肟)、菌必治(头孢三嗪)、阿奇霉素(泰力特)、环丙沙星(奔克)(悉复欢)(丙氟哌酸)、洁霉素(林可霉素)、万古霉素、复方新诺明、氯霉素、舒普深(先锋必/舒巴坦)、丁胺卡那(阿米卡星)、链霉素、美满霉素(二甲胺四环素)(米诺环素)、美罗培南、哌拉西林/他唑巴坦(特治星)。培养24h后观察抑菌圈大小。结果发现与地面对照株相比较,大肠杆菌LCT-EC52对氨苄西林、头孢唑林、头孢他啶、头孢三嗪、阿奇霉素的耐药性出现了明显的增强,出现了完全耐药。而地面对照菌株LCT-EC106对氨苄西林、头孢唑林、头孢他啶、头孢三嗪、阿奇霉素的抑菌圈大小分别为2.4cm、2.5cm、3cm、3.4cm、1.1cm。
5.溶血试验:采用点种法,将太空株和地面株点种于同一血琼脂培养基上,培养温度37℃,培养24小时后观察结果显示空间诱变大肠杆 菌LCT-EC52无溶血圈出现。
6.生化代谢(Biolog)实验:制备菌悬液,接种至Biolog96孔板,37℃培养24-48h观察结果(见图2)。该菌株生化代谢较地面株差别较大如表2,由此得出LCT-EC52菌株不能利用D-水杨、甲基丙酮酸、亚碲酸钾、溴酸钠等。
表2大肠杆菌空间菌株LCT-EC52的biolog生化特征
7.生长曲线测定:菌株活化后接种至100孔蜂窝板中,在Bioscreen中进行生长曲线的测定,测定24h,读取数据。将所得到的OD值进行平均值的计算,然后绘制曲线。大肠杆菌空间菌株LCT-EC52与地面对照菌株LCT-EC106比较,其生长曲线没有明显差别,如图3。具体实施实例二大肠杆菌空间诱变菌株LCT-EC52全基因组测序采用高通量Solexa测序技术对该样品的DNA进行Paired-End测序。首先提取细菌的基因组DNA,离心方法收集大肠杆菌LCT-EC52菌体,经过重悬、裂解、酚氯仿抽提、异丙醇沉淀、75%乙醇洗涤、RNase去除RNA和溶解基因组DNA等步骤获得LCT-EC52的基因组DNA,并检测其纯度使之符合建库指标。采用超声法Covaris将大片段基因组DNA随 机打断并产生一系列DNA片段;然后用T4DNA Polymerase、KlenowDNA Polymerase和T4PNK将打断形成的粘性末端修复成平末端,再通过3′端加碱基“A”,使得DNA片段能与3′端带有“T”碱基的特殊接头连接,用电泳法选择需回收的目的片段连接产物,再使用PCR技术扩增两端带有接头的DNA片段;建立500bp的小片段文库和6000bp的大片段文库。对测序得到的原始数据进行过滤及统计;运用SOAPdenovo V1.05软件和SOAPaligner/soap2软件对处理后的reads数据进行组装。并对基因组和基因区覆盖度进行评价;采用Glimmer3.0软件从组装结果中获得基因序列并将基因的序列与各数据库进行比对,得到对应的功能注释信息。LCT-EC52的全基因组鸟枪法测得序列总长度为5,209,752bp,平均GC含量为50.37%。其序列包含191个contigs,能够组装成37个scaffolds。用Glimmer version3.02软件预测出5,075个编码基因。对该菌株的序列进行SNP分析发现,见表1,包括SNP在基因组上的位置,突变位点及编码蛋白以及注释出的基因。具体实施实例三大肠杆菌空间诱变菌株LCT-EC52的转录组
提取样品总RNA后,用试剂盒去除rRNA后用带有Oligo(dT)的磁珠富集mRNA。加入fragmentation buffer将mRN A打断成短片段,以mRNA为模板,用六碱基随机引物(random hexamers)合成第一条cDNA链,然后加入缓冲液、dNTPs、RNase H和DNA polymerase l合成第二条cDNA链,在经过QiaQuick PCR试剂盒纯化并加EB缓冲液洗脱之后做末端修复、加polyA并连接测序接头,然后用琼脂糖凝胶电泳进行片段大小选择,最后进行PCR扩增,建好的测序文库用Illumina HiSeq2000进行测序。结果显示基因覆盖度在60%的基因有4,872个占全部基因的98%(如图4)。使用RPKM法(Reads Per Kb per Million reads)对基因进行表达量的计算,其公式为:
依据各个基因的表达量,根据大于2倍为具有差异表达的基因。结果有313个上调基因和41个下调基因(如图5)。这些差异表达的基因具体注释内容见附件1。对这些基因进行GO功能富集分析,大部分是与细菌生长、结构的改变相关。
具体实施实例四大肠杆菌空间诱变菌株LCT-EC52的蛋白质组学
我们利用iTRAQ相对定量技术对大肠杆菌空间诱变株和地面对照株进行蛋白质组学研究。首先,从样品中提取蛋白,对提取后的蛋白样品进行还原烷基化处理,打开二硫键以便后续充分酶解蛋白。用GE公司的2Dquant kit法进行蛋白质的浓度测定。等体积进行SDS(十二烷基磺酸钠)电泳。使用胰蛋白酶酶解蛋白成为肽段。使用iTRAQ试剂标记肽段。将标记后的肽段进行等量混合对混合后的肽段使用强阳离子交换色谱(StrongCation Exchange Choematography,SCX)进行预分离进行液相串联质谱(LC-MS/MS)分析。对于质谱下机的原始文件,进行峰识别,得到峰列表。其次建立参考数据库,进行肽段及蛋白质的鉴定。共鉴定到1512个蛋白,对这些蛋白进行COG功能分析发现氨基酸转运和代谢、能量的产生与转换、碳水化合物的转运和代谢的蛋白占绝大多数。最后比较各蛋白在各样品之间的相对含量的关系,当满足蛋白丰度差异倍数1.2倍以上且统计检验值P-value小于0.05时,从而获得差异表达的蛋白。结果得到3个上调表达的蛋白和4个下调表达的蛋白(图6)。上调的4个蛋白分别是鞭毛蛋白、精氨酸脱亚氨酶、甲基接受趋化蛋白II、6-磷酸果糖激酶;下调的3个蛋白分别是yfbE基因产物、IpxC基因产物、厌氧碳4二羧酸转运蛋白DcuA。
本发明的特点和应用价值:本研究是我国第一次利用自己研发的空间技术将微生物送入太空,并发现了在空间环境下大肠杆菌发生了明显的表型变化。为了探索发生这些变化的机制,我们对这一突变株进行了基因组测序、转录组测序和蛋白质组测序。这有助于深入探讨空间效应对微生物的影响。同时,这一菌株的序列已经测通,为揭示这些潜在的生物学变化提供了可能。我们将基因组、转录组和蛋白组贯穿起来研究能够更好地揭示相关细菌致病力和耐药性的变化机制,为我国载人航天事业奠定基础。
关于保藏的LCT-EC52菌株的说明
A.菌种的保藏单位名称和地址
名称:中国微生物菌种保藏管理委员会普通微生物中心
地址:北京市朝阳区北辰西路1号院3号中国科学院微生物研究所
B.交机构保藏的日期
2012年9月5日
C.保藏机构给予的保藏号
CGMCC No.6518
D.菌株分类命名:大肠埃希氏菌Escherichia coli
附件1
Claims (1)
1.一种空间环境下的大肠杆菌(Escherichia coli)LCT-EC52,其保藏号为:CGMCC6518,其表型特征为:革兰氏阴性杆菌,无芽孢,菌体单个排列;对氨苄西林、头孢唑林、头孢他啶、头孢三嗪、阿奇霉素的耐药性出现了完全耐药;不能利用D-水杨、甲基丙酮酸、亚碲酸钾、溴酸钠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210380121.4A CN102994412B (zh) | 2012-09-26 | 2012-09-26 | 一种空间环境下大肠杆菌lct-ec52菌株 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210380121.4A CN102994412B (zh) | 2012-09-26 | 2012-09-26 | 一种空间环境下大肠杆菌lct-ec52菌株 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102994412A CN102994412A (zh) | 2013-03-27 |
CN102994412B true CN102994412B (zh) | 2015-02-25 |
Family
ID=47923525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210380121.4A Expired - Fee Related CN102994412B (zh) | 2012-09-26 | 2012-09-26 | 一种空间环境下大肠杆菌lct-ec52菌株 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102994412B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113486849A (zh) * | 2021-07-27 | 2021-10-08 | 哈尔滨工业大学 | 一种鉴定空间诱变水稻表型变化的方法 |
CN118147009A (zh) * | 2024-04-08 | 2024-06-07 | 中国人民解放军总医院第八医学中心 | 一种空间奇异变形杆菌st8 |
-
2012
- 2012-09-26 CN CN201210380121.4A patent/CN102994412B/zh not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
Draft Genome Sequence of Escherichia coli LCT-EC106;Tianzhi Li等人;《Journal of Bacteriology》;20120831;第194卷(第16期);第4443页 * |
Growth and division of Escherichia coli under microgravity conditions;G. Gasset等人;《Res. Microlyiol.》;19941231;第145卷;第111页右栏 * |
Investigation of space flight effects on;David Klaus等人;《Microbiology》;19971231;第143卷;第449-455页 * |
大肠杆菌菌种空间变异的研究;翁曼丽等;《航天医学与医学工程》;19980831;第11卷(第4期);第245-248页 * |
微重力对病原菌毒力和抗生素敏感性影响的研究进展;方向群等人;《航天医学与医学工程》;20120630;第25卷(第3期);第220-224页,参见第223页左栏 * |
Also Published As
Publication number | Publication date |
---|---|
CN102994412A (zh) | 2013-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shkoporov et al. | Reproducible protocols for metagenomic analysis of human faecal phageomes | |
Pfleiderer et al. | RETRACTED ARTICLE: Culturomics identified 11 new bacterial species from a single anorexia nervosa stool sample | |
EP3360560A1 (en) | Composition for treating acne | |
Ó Cuív et al. | The effects from DNA extraction methods on the evaluation of microbial diversity associated with human colonic tissue | |
WO2019114049A1 (zh) | 一种用于分析肠道微生物的引物组合物及其应用 | |
Zhong et al. | Bifidobacterium animalis subsp. lactis Probio-M8 undergoes host adaptive evolution by glc U mutation and translocates to the infant’s gut via oral-/entero-mammary routes through lactation | |
Shen et al. | Prevalence, genomic characteristics, and transmission dynamics of mcr-1-positive Salmonella enterica Typhimurium from patients with infectious diarrhea | |
CN102994412B (zh) | 一种空间环境下大肠杆菌lct-ec52菌株 | |
Reyes-Escogido et al. | Purification of bacterial genomic DNA in less than 20 min using chelex-100 microwave: examples from strains of lactic acid bacteria isolated from soil samples | |
Han et al. | Analyses of genetics and pathogenesis of Salmonella enterica QH with narrow spectrum of antibiotic resistance isolated from yak | |
Cresci et al. | Corynebacterium phoceense sp. nov., strain MC1T a new bacterial species isolated from human urine | |
Yadav et al. | Methods in metagenomics and environmental biotechnology | |
Prajapati et al. | Whole-genome sequence analysis of Clostridium chauvoei isolated from clinical case of black quarter (BQ) from India | |
Hashosh et al. | Molecular detection of CRISPR-Cas system in Staphylococcus aureus isolated from different sources | |
Ricaboni et al. | Noncontiguous finished genome sequence and description of Streptococcus timonensis sp. nov. isolated from the human stomach | |
CN102994413B (zh) | 空间环境下大肠杆菌lct-ec59及其基因组序列 | |
Alou et al. | Massilibacterium senegalense gen. nov., sp. nov., a new bacterial genus isolated from the human gut | |
Vikram et al. | Draft genome sequence of Massilia sp. KIM isolated from South African grassland biome soils | |
CN103555602B (zh) | 一种空间环境下的蜡状芽孢杆菌lct-bc235菌株 | |
Alou et al. | Paenibacillus phocaensis sp. nov., isolated from the gut microbiota of a healthy infant | |
Lo et al. | High-quality genome sequence and description of Bacillus ndiopicus strain FF3T sp. nov. | |
CN103555603A (zh) | 一种太空蜡状芽孢杆菌株lct-bc25 | |
Musser et al. | Characterization of Mycobacterium salfingeri sp. nov.: A novel nontuberculous mycobacteria isolated from a human wound infection | |
Vineis et al. | A novel conjugative transposon carrying an autonomously amplified plasmid | |
Boxberger et al. | Draft genome and description of Corynebacterium haemomassiliense strain Marseille-Q3615T sp. nov., a new bacterium isolated from a 59-year-old man with chronic obstructive pulmonary disease symptoms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150225 Termination date: 20150926 |
|
EXPY | Termination of patent right or utility model |